Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Non-Current Assets (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Non-Current Assets for 7 consecutive years, with $19.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets rose 149.85% to $19.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $54.6 million, a 68.66% increase, with the full-year FY2024 number at $7.8 million, down 5.54% from a year prior.
  • Non-Current Assets was $19.9 million for Q3 2025 at Vivos Therapeutics, up from $19.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $19.9 million in Q3 2025 to a low of $5.2 million in Q1 2021.
  • A 5-year average of $9.0 million and a median of $8.2 million in 2024 define the central range for Non-Current Assets.
  • Biggest YoY gain for Non-Current Assets was 149.85% in 2025; the steepest drop was 6.32% in 2025.
  • Vivos Therapeutics' Non-Current Assets stood at $6.4 million in 2021, then soared by 30.34% to $8.3 million in 2022, then fell by 0.33% to $8.3 million in 2023, then decreased by 5.54% to $7.8 million in 2024, then soared by 154.23% to $19.9 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Non-Current Assets are $19.9 million (Q3 2025), $19.3 million (Q2 2025), and $7.7 million (Q1 2025).